
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **ERBB2 (HER2)**: A member of the epidermal growth factor receptor (EGFR) family, often overexpressed in certain breast cancer subtypes, particularly HER2-positive breast cancer.<br>- **GRB7**: An adaptor protein that interacts with receptor tyrosine kinases like ERBB2, involved in signal transduction pathways that promote cell proliferation and survival.<br>- **MDM2**: An E3 ubiquitin-protein ligase that negatively regulates the p53 tumor suppressor, often implicated in cancer progression.<br>- **HES1**: A transcriptional repressor involved in the Notch signaling pathway, which plays a role in cell differentiation and proliferation.<br>- **SQLE**: Squalene epoxidase, a key enzyme in cholesterol biosynthesis, often upregulated in cancer cells to support rapid cell growth.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ERBB2 (HER2)**: Strongly associated with HER2-positive breast cancer cells.<br>- **TFAP2B**: A transcription factor that can be involved in the regulation of genes associated with epithelial cell differentiation.<br>- **APOD**: Apolipoprotein D, often expressed in breast tissue and associated with lipid metabolism.<br>- **HSPB1 (HSP27)**: A heat shock protein that can be upregulated in response to stress and is often associated with cancer cell survival.<br>- **STARD3**: A cholesterol transporter that is often co-amplified with ERBB2 in breast cancer.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, the markers ERBB2, GRB7, and STARD3 are frequently associated with HER2-positive breast cancer cells. The presence of these markers, along with others like MDM2 and HSPB1, supports the identification of a cancerous epithelial cell type, specifically within the breast tissue context.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Given the expression of ERBB2, GRB7, and other associated markers, the most probable general cell type is a **cancerous epithelial cell** from breast tissue, specifically a subtype of breast cancer cells.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-positive Breast Cancer Cells**: The presence of ERBB2, GRB7, and STARD3 strongly suggests this subtype, as these markers are characteristic of HER2-positive breast cancer.<br>2. **Luminal B Breast Cancer Cells**: This subtype can also express ERBB2 and other markers like TFAP2B, though typically with lower ERBB2 expression compared to HER2-positive cells.<br>3. **Basal-like Breast Cancer Cells**: While less likely due to the strong ERBB2 signal, some markers like HSPB1 can be expressed in basal-like subtypes.<br><br>The most likely subtype based on the markers is **HER2-positive Breast Cancer Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of cancerous epithelial cells, specifically HER2-positive breast cancer cells. This conclusion is supported by the high expression of ERBB2, GRB7, and STARD3, which are hallmark markers of this breast cancer subtype. Other markers such as MDM2 and HSPB1 further support the identification of a cancerous phenotype.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    To validate the annotation result, let's follow the outlined steps:<br><br>### Step 1: Marker Consistency<br>- **ERBB2 (HER2)**, **GRB7**, **MDM2**, **HES1**, **SQLE**, **TFAP2B**, **APOD**, **HSPB1 (HSP27)**, and **STARD3** are all present in the provided marker list.<br>- The markers used in the annotation are consistent with the provided marker list.<br><br>### Step 2: Mixed Cell Type Consideration<br>- The annotation identifies the cell type as primarily **HER2-positive Breast Cancer Cells**, supported by the presence of key markers such as **ERBB2**, **GRB7**, and **STARD3**.<br>- The analysis also considers the possibility of **Luminal B Breast Cancer Cells** and **Basal-like Breast Cancer Cells** based on the expression of other markers like **TFAP2B** and **HSPB1**.<br>- The presence of multiple markers associated with different breast cancer subtypes suggests a potential mixed cell population. However, the strong presence of **ERBB2**, **GRB7**, and **STARD3** strongly supports the primary identification of **HER2-positive Breast Cancer Cells**.<br><br>### Conclusion<br>The annotation is consistent with the provided marker list and the identified cell type is well-supported by the markers. The potential for mixed cell types is acknowledged, but the primary identification remains valid.<br><br>Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">cancerous epithelial cell</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>HER2-positive Breast Cancer Cells</li><li>Luminal B Breast Cancer Cells</li><li>Basal-like Breast Cancer Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the markers associated with breast cancer, particularly HER2-positive breast cancer. The analysis correctly identifies key markers such as ERBB2, GRB7, and STARD3, which are well-known to be associated with HER2-positive breast cancer cells. This indicates a high level of scientific accuracy in the annotation.<br><br>The annotation process also shows a balanced consideration of multiple markers. It does not overly focus on a single marker but instead integrates several markers to support the identification of the cell type. For instance, the inclusion of markers like MDM2, HSPB1, and TFAP2B provides a broader context and supports the identification of potential subtypes such as Luminal B and Basal-like breast cancer cells. This demonstrates a comprehensive approach to understanding the cell populations present.<br><br>The annotation captures the general picture of the cell populations effectively by considering the possibility of mixed cell types and acknowledging the presence of markers associated with different breast cancer subtypes. This reflects a nuanced understanding of the complexity of cancer cell populations.<br><br>However, there are a few areas where the annotation could be improved. While the analysis considers the rank of the markers, it could place more emphasis on the top-ranked markers to ensure that the most critical markers are given appropriate weight in the final annotation. Additionally, the potential for mixed cell types is acknowledged but not deeply explored, which could provide a more comprehensive view of the cell populations.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present, with minor areas for improvement in marker ranking emphasis and exploration of mixed cell types.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    